MINI FUTURE OPTIONSSCHEIN PUT - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 20:34:47 14/06/2024 BST | ||
| 16.02 EUR | -1.78% |
|
| Current month | -12.65% | ||
| 1 month | -22.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 16.02 | -1.78% |
| 13/06/24 | 16.31 | -1.57% |
| 12/06/24 | 16.57 | +4.02% |
| 11/06/24 | 15.93 | +1.53% |
| 10/06/24 | 15.69 | +0.51% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 08:34 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DJ8201 |
| ISIN | DE000DJ82018 |
| Date issued | 01/02/2024 |
| Strike | 652.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.51 € |
|---|---|
| Lowest since issue | 15.25 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat